Aller à: contenu | haut | bas | recherche
EN    FR  
Vous êtes iciUNIL > Enseignement > Master laboratories > Chin Eap

Dr. Chin Eap

PI of the laboratory: Chin Eap
Tél: 021 643 64 38;

Direct supervisor (assistant): Séverine Crettol
Tél: 021 643 65 09,
Laboratory: Unit of Biochemistry and Clinical Psychopharmacology

Address: Centre for Psychiatric Neuroscience of the Department of Psychiatry-CHUV, Hospital of Cery, 1008 Prilly


In vitro study of transport of psychotropic drugs by human Permeability-glycoprotein (PGP)

Description of Project:
Permeability glycoprotein (PGP) is a trans-membrane protein expressed in various organs including the blood brain barrier. It acts as detoxifier by pumping various drugs or xenobiotics from the inner to the outer part of the cell, therefore protecting various “sanctuary” organs including the central nervous system. The activity of PGP is therefore crucial in controlling the efficacy / CNS side-effects of psychotropic drugs, which have to enter the brain to be active. Various psychotropic drugs have already been studied in our unit to determine whether they are substrates of this transporter. The aim of this work is to test new psychotropic drugs, which have been recently introduced into the market. The determination of transport by PGP will be done by using epithelial renal cells over- expressing PGP as compared to control cells. The student will work with cells in culture. He/she will have the opportunity to be introduced to very sensitive analytical methods for the determination of drugs (high performance liquid chromatography – mass spectrometry or HPLC-MS). This study will allow to extend our understanding of the transport of psychotropic drugs by PGP.

- Tanigawara Y. Role of P-glycoprotein in drug disposition. Ther Drug Monit 2000; 22:137-140.
- Johnstone RW, Ruefli AA, Smyth MJ. Multiple physiological functions for multidrug transporter P-glycoprotein? TIBS 2000; 25:1-6.
- Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004; 75(1):13-33.
- Clement Jerdi M, Desmeules J, Dayer P. La glycoprotéine P : un transporteur de médicaments à ne pas négliger. Med Hyg 2004; 62: 704-9
- Zhang Y, Bachmeier C, Miller DW. In vitro and in vivo models for assessing drug efflux transporter activity. Advanced Drug Delivery Reviews 2003; 55:31-51.
- Lin YC, Ellingrod VL, Bishop JR, Miller del D. The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia. Ther Drug Monit. 2006 Oct;28(5):668-72.

Link to the group web site

Rue du Bugnon 9 - CH-1005 Lausanne  - Suisse  -  Tél. +41 21 692 51 00  -  Fax +41 21 692 51 05
Swiss University